Research map: Switching to antipsychotic monotherapy and quality of life: A randomized controlled trial

Back to the article

Papers in this map

  1. Different ways to estimate treatment effects in randomised controlled trials · Jos W. R. Twisk · 2018 · 559 citations · Cited by this paper
  2. Cohesion profiles across language-related symptoms in schizophrenia · 2026 · Related
  3. Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy · Susan M. Essock · 2011 · 179 citations · Cited by this paper
  4. Association between depressive symptoms, CRP and metabolism-related indicators in Han Chinese patients with chronic schizophrenia · 2026 · Related
  5. Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis · Mikkel Højlund · 2024 · 58 citations · Cited by this paper
  6. Initiation patterns of long-acting injectable antipsychotics in a claims-based proxy cohort approximating first-episode schizophrenia: A longitudinal descriptive study using a Japanese claims database · 2026 · Related
  7. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial · Robert J. Constantine · 2015 · 41 citations · Cited by this paper
  8. A mixed methods study of program-level factors influencing patient and family engagement in first episode psychosis coordinated specialty care · 2026 · Related
  9. Incidence of Tardive Dyskinesia and Tardive Dystonia in African Caribbean Patients on Long-Term Antipsychotic Treatment · Peter N. van Harten · 2006 · 41 citations · Cited by this paper
  10. Converting negative symptom dimension scores across SANS and PANSS · 2026 · Related
  11. The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic randomized open-label trial (SwAP trial) · Mushde Shakir · 2022 · 14 citations · Cited by this paper
  12. The U-shaped relationships between prolactin level and insulin resistance in patients with schizophrenia under olanzapine treatment · 2026 · Related
  13. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia · George Anis Awad · 2016 · 12 citations · Cited by this paper
  14. Medium-term prediction of clinically relevant outcomes in first-episode schizophrenia patients · 2026 · Related
  15. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia · George Anis Awad · 2014 · 11 citations · Cited by this paper
  16. Association of COVID-19 vaccination with improved treatment adherence in patients with schizophrenia: A propensity score-matched cohort study · 2026 · Related
  17. Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects · Mushde Shakir · 2024 · 3 citations · Cited by this paper
  18. Subjective space and time experience in schizophrenia spectrum disorders and mood disorders: Psychometric properties and clinical correlates of the semi-structured STEP interview · 2026 · Related
  19. Motivation and pleasure deficits reflect altered network embedding of normal brain deviations in schizophrenia · 2026 · Related

Source: OpenAlex (CC0)